A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)
This research, called The ReSPECT Study, is looking into how well a new medicine, Rezafungin (also known as REZZAYO), can stop serious fungal infections in people who have had a blood or bone marrow transplant. These transplants can sometimes weaken the immune system, making patients more vulnerable to infections. The study is comparing Rezafungin to other commonly used medicines that prevent fungal infections, to see which is safer and works best. Researchers want to find out if patients taking Rezafungin are less likely to get a fungal infection or die within 90 days after their transplant, compared to those on current treatments. The study aims to provide important information to doctors and patients.
At a glance
What is this study about?
This clinical trial, called The ReSPECT Study, focuses on adults who have recently had a special type of transplant called an allogeneic blood and marrow transplant. This procedure is often used to treat serious illnesses like some cancers. While these transplants can be life-saving, they also temporarily weaken the body's immune system, making patients very vulnerable to serious infections, including fungal infections. These fungal infections can be very serious and sometimes life-threatening.
The main goal of this study is to see if a new medicine, Rezafungin, can effectively prevent these serious fungal infections. The researchers are comparing Rezafungin to other medicines that are currently used to prevent fungal infections. They want to find out if Rezafungin is better at keeping patients free from fungal infections and alive for at least 90 days after their transplant, and whether it has fewer side effects.
Understanding how well new medicines work to prevent these infections is really important for improving care for transplant patients. By carefully comparing different treatments, this study aims to provide valuable information that can help doctors make the best decisions for their patients in the future.
Key takeaways
- Tests a new medicine (Rezafungin) to prevent fungal infections.
- For adults having blood or bone marrow transplants.
- Compares Rezafungin to current standard treatments.
- Aims to find safer and more effective ways to protect patients.
- Lasts at least 90 days after transplant.
Who may be eligible?
This study is looking for adult patients, 18 years and older, who are about to have an allogeneic blood and marrow transplant. This type of transplant involves receiving blood-forming stem cells from another person.
Both men and women can take part in this research. The doctors involved will also check other health details to make sure the study is a good fit and safe for you. This often means checking your general health and whether you have any other conditions that might affect the results of the study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you an adult (18 years or older)?
- Are you scheduled to have an allogeneic blood or marrow transplant?
- Are you able to attend regular hospital visits and follow study instructions?
- Are you comfortable with the possibility of receiving a new medicine or a standard treatment (or a placebo if applicable)?
What does participation involve?
If you decide to take part, you would be randomly assigned to receive either the new medicine, Rezafungin, or one of the standard medicines currently used to prevent fungal infections. Some patients might also receive a placebo, which looks like the active medicine but contains no drug, to help compare effects fairly. Neither you nor your doctor will know which treatment you are receiving until after the study is complete. This is called a 'double-blind' study.
Throughout the study, you would have regular appointments, blood tests, and check-ups to monitor your health, look for any signs of fungal infections, and see how you are responding to the medication. This typically involves several hospital visits. The study will continue for at least 90 days after your transplant, with follow-up to check your health and ensure the medicine is working as intended and is safe. The specific schedule of visits and tests will be explained in detail by the study team.
Potential risks and benefits
Locations (5)
- —UnverifiedFrance
- —UnverifiedItaly
- —UnverifiedGermany
- —UnverifiedBelgium
- —UnverifiedSpain
Common questions
What is an allogeneic blood and marrow transplant?
It's a medical procedure where you receive healthy blood-forming cells from another person to replace your own damaged cells, often used for conditions like certain cancers.
What are invasive fungal diseases?
These are serious infections caused by fungi that can spread throughout the body, especially in people with weakened immune systems after a transplant.
What is Rezafungin?
Rezafungin is a new medicine being tested to see if it can help prevent these serious fungal infections from happening.
Why don't I know which medicine I'm getting?
This is a 'double-blind' study, meaning neither you nor your doctors know which treatment you're on. This helps keep the study fair and accurate, so we can clearly see the effects of each medicine.
How long will I be in the study?
The main part of the study will last about 90 days after your transplant, with ongoing monitoring during that time and potentially some follow-up after that.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.